JP2002512591A5 - - Google Patents

Download PDF

Info

Publication number
JP2002512591A5
JP2002512591A5 JP1998517754A JP51775498A JP2002512591A5 JP 2002512591 A5 JP2002512591 A5 JP 2002512591A5 JP 1998517754 A JP1998517754 A JP 1998517754A JP 51775498 A JP51775498 A JP 51775498A JP 2002512591 A5 JP2002512591 A5 JP 2002512591A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998517754A
Other languages
English (en)
Other versions
JP2002512591A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/018272 external-priority patent/WO1998015272A1/en
Publication of JP2002512591A publication Critical patent/JP2002512591A/ja
Publication of JP2002512591A5 publication Critical patent/JP2002512591A5/ja
Ceased legal-status Critical Current

Links

Description

Figure 2002512591
Figure 2002512591
Figure 2002512591
Figure 2002512591
JP51775498A 1996-10-09 1997-10-09 ストレス活性化されたタンパク質キナーゼの阻害法 Ceased JP2002512591A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2845996P 1996-10-09 1996-10-09
US60/028,459 1996-10-09
PCT/US1997/018272 WO1998015272A1 (en) 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases

Publications (2)

Publication Number Publication Date
JP2002512591A JP2002512591A (ja) 2002-04-23
JP2002512591A5 true JP2002512591A5 (ja) 2005-06-16

Family

ID=21843560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51775498A Ceased JP2002512591A (ja) 1996-10-09 1997-10-09 ストレス活性化されたタンパク質キナーゼの阻害法

Country Status (16)

Country Link
US (1) US6214854B1 (ja)
EP (1) EP0946172A4 (ja)
JP (1) JP2002512591A (ja)
KR (1) KR20000048967A (ja)
CN (1) CN1157188C (ja)
AU (1) AU4751897A (ja)
BR (1) BR9712283A (ja)
CA (1) CA2267967A1 (ja)
CZ (1) CZ123099A3 (ja)
IL (1) IL129326A0 (ja)
NO (1) NO991655L (ja)
NZ (1) NZ335080A (ja)
PL (1) PL332638A1 (ja)
TR (1) TR199900762T2 (ja)
WO (1) WO1998015272A1 (ja)
ZA (1) ZA979055B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393488A1 (en) * 1999-12-07 2001-06-14 Duke University Use of .alpha.1ar subtype-selective drugs in patients with acute myocardial infarction
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
KR101468827B1 (ko) * 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
CA2492084A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
AU2004281780B2 (en) 2003-10-14 2009-03-19 F. Hoffmann-La Roche Ltd Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2015031914A1 (en) * 2013-08-30 2015-03-05 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5405863A (en) 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies

Similar Documents

Publication Publication Date Title
JP2000502280A5 (ja)
JP2000501771A5 (ja)
JP2000501599A5 (ja)
JP2000501018A5 (ja)
JP2000500076A5 (ja)
JP2000501324A5 (ja)
JP2000500055A5 (ja)
JP2000502472A5 (ja)
JP2000501338A5 (ja)
JP2000501825A5 (ja)
JP2000500874A5 (ja)
JP2000502485A5 (ja)
JP2000502425A5 (ja)
JP2000501774A5 (ja)
JP2000502570A5 (ja)
JP2000500912A5 (ja)
JP2000502568A5 (ja)
JP2000501876A5 (ja)
JP2000501744A5 (ja)
JP2000502316A5 (ja)
JP2000500857A5 (ja)
JP2000501229A5 (ja)
JP2000502714A5 (ja)
JP2000500318A5 (ja)
JP2000501569A5 (ja)